Skip to main content
Displaying 13 - 24 of 452
Display:
12
24
48
Metabolism, Alcohol & Toxicity
5
AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Pagination
First page
« First
Previous page
‹ previous
Page
1
Current page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy